Zobraziť v EDS

TRIPS and knowledge diffusion from low‐ and middle‐income countries.

Uložené v:
Podrobná bibliografia
Názov: TRIPS and knowledge diffusion from low‐ and middle‐income countries.
Autori: Blomfield, Michael1 (AUTHOR), McGahan, Anita M.2 (AUTHOR) amcgahan@rotman.utoronto.ca, Vakili, Keyvan3 (AUTHOR)
Zdroj: Strategic Management Journal (John Wiley & Sons, Inc.). Oct2025, p1. 31p. 6 Illustrations.
Predmety: *LOW-income countries, *INTELLECTUAL property, AGREEMENT on Trade-Related Aspects of Intellectual Property Rights (1994), PHARMACEUTICAL technology, DISEASE outbreaks, KNOWLEDGE transfer, NEGLECTED diseases, ACADEMIC discourse
Abstrakt: Research Summary Managerial Summary We examine a significant yet underappreciated effect of IPR implementation: the dissemination after TRIPS implementation of established scientific knowledge from low‐ and middle‐income countries (LMICs) into the global scientific system of pharmaceutical development. The staggered implementation of the policy allows identification of increased diffusion of pre‐existing LMIC knowledge on global diseases into the global corporate invention pipeline. For neglected diseases, the uptake remains in academic science. Other results demonstrate institutional effects in the scientific communities in LMICs through increases in scientific productivity, cross‐border collaborations, and scientist mobility. These and other results recast TRIPS’ impact as sensitive to the incentives of global corporations and institutionally significant for LMICs. We discuss implications for research on innovation strategy.The implementation in an LMIC of an intellectual‐property system (e.g., of patents) carries implications for dissemination of pre‐existing scientific knowledge from the implementing country into the global scientific system. Corporate invention more intensively incorporates pre‐existing LMIC knowledge when the subject is global diseases such as cardiovascular conditions and cancer. However, when the subject is neglected diseases such as infectious conditions, the significant uptake remains in academic science. Overall, this research suggests that the implementation of patent and other intellectual‐property protections influences the integration of LMIC science into the global system differentially based on the relevance for global commercialization. [ABSTRACT FROM AUTHOR]
Copyright of Strategic Management Journal (John Wiley & Sons, Inc.) is the property of John Wiley & Sons, Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáza: Business Source Index
Popis
Abstrakt:Research Summary Managerial Summary We examine a significant yet underappreciated effect of IPR implementation: the dissemination after TRIPS implementation of established scientific knowledge from low‐ and middle‐income countries (LMICs) into the global scientific system of pharmaceutical development. The staggered implementation of the policy allows identification of increased diffusion of pre‐existing LMIC knowledge on global diseases into the global corporate invention pipeline. For neglected diseases, the uptake remains in academic science. Other results demonstrate institutional effects in the scientific communities in LMICs through increases in scientific productivity, cross‐border collaborations, and scientist mobility. These and other results recast TRIPS’ impact as sensitive to the incentives of global corporations and institutionally significant for LMICs. We discuss implications for research on innovation strategy.The implementation in an LMIC of an intellectual‐property system (e.g., of patents) carries implications for dissemination of pre‐existing scientific knowledge from the implementing country into the global scientific system. Corporate invention more intensively incorporates pre‐existing LMIC knowledge when the subject is global diseases such as cardiovascular conditions and cancer. However, when the subject is neglected diseases such as infectious conditions, the significant uptake remains in academic science. Overall, this research suggests that the implementation of patent and other intellectual‐property protections influences the integration of LMIC science into the global system differentially based on the relevance for global commercialization. [ABSTRACT FROM AUTHOR]
ISSN:01432095
DOI:10.1002/smj.70026